EUVIMEDDescobrir EUVIMED
KohortenstudieOpen access · CC BY 4.0

Clinical Utility and Cost‐Effectiveness of Pretreatment NUDT15 Pharmacogenetic Testing to Prevent Thiopurine‐Induced Myelosuppression: A Genotype‐First Reverse Phenotyping Cohort Study Within the UK NIHR Inflammatory Bowel Disease Bioresource

Christopher Roberts iD, Jaime Peters iD, Aleksejs Sazonvos iD, Neil Goodman, Mohmmed Sharip iD, Rebecca Smith iD, Maria Bishara iD, Claire Bewshea iD, Simeng Lin iD, Neil Chanchlani iD, Phoebe Hodges iD, Fakhirah Badrulhisham iD and 23 more

Alimentary Pharmacology & Therapeutics · 2025-09 · 62 (6) · 630-645

DOI: 10.1111/apt.70232 ↗

At a glance

Kohortenstudie in Alimentary Pharmacology & Therapeutics, published online on 2025-06-23. Written by Christopher Roberts and 34 co-authors. Institution: University of Exeter Inflammatory Bowel Disease and Pharmacogenetics Research Group, Exeter, UK. Major MEDLINE topics: Pyrophosphatases, Inflammatory Bowel Diseases, Pharmacogenomic Testing, Mercaptopurine. Cited 9 times so far (Crossref); 24 references. The full text is freely available (open access, CC BY 4.0). Funded by: Wellcome Trust, University of Exeter, Medical Research Council.

ResumoSubjectsDados bibliográficosCiteRelated studies

Abstract (original language)

Background

The clinical utility and cost‐effectiveness of pre‐thiopurine NUDT15 pharmacogenetic testing in European and admixed populations are unknown.

Aims

To report the prevalence, penetrance, expressivity, and pathogenicity of NUDT15 variant allele carriage and the diagnostic accuracy and cost‐effectiveness of an inexpensive loop‐mediated isothermal amplification (LAMP) test.

Methods

Retrospective case‐matched cohort study of rates of severe myelosuppression in patients with and without loss‐of‐function NUDT15 variant allele(s) treated with a thiopurine.

Results

Overall, 1.3% of Europeans and 11.7% of South Asians carried a variant allele. Severe myelosuppression was associated with NUDT15 variant allele carriage (11.3% vs 0.95%; p < 0.001). Carriage of a single *3, *6 or *9 variant allele was associated with a shorter time to severe myelosuppression. Numbers needed to genotype to prevent myelosuppression in Europeans and South Asians were 786 and 23. Variant calling using the LAMP assay was fully concordant with Sanger sequencing ( n = 154). It improved the safety of thiopurine dosing and was cost‐effective when used to reduce the frequency and cost of thiopurine blood monitoring for patients without risk variants.

Conclusion

We recommend TPMT and NUDT15 genetic testing in patients of Asian and admixed ancestry. In Europeans, reflex NUDT15 testing should be considered in patients with reduced TPMT activity or loss‐of‐function genotype. Thiopurines should be avoided in patients with > 1 NUDT15 variant allele and in patients with both NUDT15 and TPMT variant alleles. In patients with a single NUDT15 variant allele, we recommend thiopurine dose reduction (< 1 mg/kg/day) and intensified blood test monitoring.

Subjects

MeSH terms (MEDLINE)

PyrophosphatasesInflammatory Bowel DiseasesPharmacogenomic TestingMercaptopurineAzathioprineHumansCost-Benefit AnalysisMaleFemaleRetrospective StudiesAdultUnited KingdomGenotypeMiddle AgedPhenotypeCohort StudiesCase-Control StudiesNudix Hydrolases

Author keywords

NUDT15cost‐effectivenessexpressivityinflammatory bowel diseasemyelosuppressionpenetrancepharmacogenetic testingvariant pathogenicity

Substances

NUDT15 protein, humanPyrophosphatasesMercaptopurineAzathioprineNudix Hydrolases

Authors and institutions

  • University of Exeter Inflammatory Bowel Disease and Pharmacogenetics Research Group, Exeter, UK.
  • Department of Gastroenterology, Royal Devon University Healthcare NHS Foundation Trust, Exeter, Devon, UK.
  • Exeter Test Group, Department of Health and Community Sciences, The Medical School, University of Exeter, Exeter, UK.
  • Wellcome Sanger Institute, Hinxton, Cambridgeshire, UK.
  • Exeter Genomics Laboratory, Royal Devon University Healthcare NHS Foundation Trust, Exeter, Devon, UK.
  • Department of Gastroenterology, Cambridge University Hospitals NHS Foundation Trust, Cambridge, UK.

ORCID profiles: Christopher Roberts, Jaime Peters, Aleksejs Sazonvos, Mohmmed Sharip, Rebecca Smith, Maria Bishara, Claire Bewshea, Simeng Lin, Neil Chanchlani, Phoebe Hodges, Fakhirah Badrulhisham, Aamir Saifuddin, Sean Carlson, Andrea Centritto, Alexandra Marley, Muhammad Saad, Karishma Sethi-Aora, Laura White, Alaa Abdelmeguid, Laetitia Pele, Shaji Sebastian, Christian Selinger, Peter Irving, Laura Fachal, Gareth Walker, Rachel Palmer, Nick Kennedy, Mary Doona, Christopher Lamb, Chris Hyde, Miles Parkes, James Goodhand, Tariq Ahmad

Funding

  • Wellcome Trust
  • University of Exeter
  • Medical Research Council
  • Nova laboratories

Cite

APA

Roberts, C., Peters, J., Sazonvos, A., Goodman, N., Sharip, M., Smith, R., Bishara, M., Bewshea, C., Lin, S., Chanchlani, N., Hodges, P., Badrulhisham, F., Saifuddin, A., Carlson, S., Centritto, A., Marley, A., Saad, M., Sethi-Aora, K., White, L., …, & Ahmad, T. (2025). Clinical Utility and Cost‐Effectiveness of Pretreatment NUDT15 Pharmacogenetic Testing to Prevent Thiopurine‐Induced Myelosuppression: A Genotype‐First Reverse Phenotyping Cohort Study Within the UK NIHR Inflammatory Bowel Disease Bioresource. Alimentary Pharmacology & Therapeutics, 62(6), 630-645. https://doi.org/10.1111/apt.70232

Vancouver

Roberts C, Peters J, Sazonvos A, Goodman N, Sharip M, Smith R, et al. Clinical Utility and Cost‐Effectiveness of Pretreatment NUDT15 Pharmacogenetic Testing to Prevent Thiopurine‐Induced Myelosuppression: A Genotype‐First Reverse Phenotyping Cohort Study Within the UK NIHR Inflammatory Bowel Disease Bioresource. Alimentary Pharmacology & Therapeutics. 2025;62(6):630-645. doi:10.1111/apt.70232

BibTeX
@article{Roberts2025,
  author = {Roberts, Christopher and Peters, Jaime and Sazonvos, Aleksejs and Goodman, Neil and Sharip, Mohmmed and Smith, Rebecca and Bishara, Maria and Bewshea, Claire and Lin, Simeng and Chanchlani, Neil and Hodges, Phoebe and Badrulhisham, Fakhirah and Saifuddin, Aamir and Carlson, Sean and Centritto, Andrea and Marley, Alexandra and Saad, Muhammad and Sethi-Aora, Karishma and White, Laura and Abdelmeguid, Alaa and Pele, Laetitia and Sebastian, Shaji and Selinger, Christian and Irving, Peter and Fachal, Laura and Walker, Gareth and Palmer, Rachel and Kennedy, Nick and Houghton, Jayne and Doona, Mary and Lamb, Christopher and Hyde, Chris and Parkes, Miles and Goodhand, James and Ahmad, Tariq},
  title = {Clinical Utility and Cost‐Effectiveness of Pretreatment NUDT15 Pharmacogenetic Testing to Prevent Thiopurine‐Induced Myelosuppression: A Genotype‐First Reverse Phenotyping Cohort Study Within the UK NIHR Inflammatory Bowel Disease Bioresource},
  journal = {Alimentary Pharmacology & Therapeutics},
  year = {2025},
  volume = {62},
  number = {6},
  pages = {630--645},
  doi = {10.1111/apt.70232}
}
Start for free →